GCBT is the strategic foothold for Green Cross’ business expansion to the North American and European markets. We are building a state of the art bio-manufacturing facility for plasma proteins and will be the only intravenous immunoglobulin (IVIG) and albumin producer in Canada.
Green Cross Biotherapeutics Inc. (GCBT) will initially manufacture two products: Intravenous Immunoglobulin (IVIG), a key therapeutic solution for the treatment of patients with infectious and immune diseases, and albumin, used as a blood-volumizing agent and in the treatment of burns.
PDF version of internal news release. MONTRÉAL (April 4, 2016) – Green Cross Biotherapeutics visited the new Montreal Children’s Hospital to deliver... Read More →
A Major Project in Canada
Project Oasis is a plan to expand Green Cross’ business to North America and Europe. Its Montreal plant will be the project`s focal point. $400 million will be invested in Canada’s only intravenous immunoglobulin (IVIG) and albumin manufacturing plant and in sourcing essential raw materials. We are honoured to receive strategic support from Investissement Quebec and that the Korean National Pension Services has invested in us.